MIRA INFORM REPORT

 

 

Report Date :

11.09.2012

 

IDENTIFICATION DETAILS

 

Name :

MULTI APEX PHARMA FOR PHARMACEUTICALS INDUSTRIES

 

 

Registered Office :

31 Ahmed Omar Bakier Street, Heliopolis, Cairo

 

 

Country :

Egypt

 

 

Financials (as on) :

31.12.2011

 

 

Year of Establishment :

2000

 

 

Com. Reg. No.:

2436, Cairo

 

 

Legal Form :

Egyptian Joint Stock Company

 

 

Line of Business :

Manufacture of pharmaceutical products

 

 

No. of Employees :

290 employees

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2012

 

Country Name

Previous Rating

(31.12.2011)

Current Rating

(31.03.2012)

Egypt

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

Egypt - ECONOMIC OVERVIEW

 

Occupying the northeast corner of the African continent, Egypt is bisected by the highly fertile Nile valley, where most economic activity takes place. Egypt's economy was highly centralized during the rule of former President Gamal Abdel NASSER but opened up considerably under former Presidents Anwar EL-SADAT and Mohamed Hosni MUBARAK. Cairo from 2004 to 2008 aggressively pursued economic reforms to attract foreign investment and facilitate GDP growth. Despite the relatively high levels of economic growth in recent years, living conditions for the average Egyptian remained poor and contributed to public discontent. After unrest erupted in January 2011, the Egyptian Government drastically increased social spending to address public dissatisfaction, but political uncertainty at the same time caused economic growth to slow significantly, reducing the government's revenues. Tourism, manufacturing, and construction are among the hardest hit sectors of the Egyptian economy, and economic growth is likely to remain slow at least through 2012. The government is utilizing foreign exchange reserves to support the Egyptian pound and Egypt may seek a loan from the International Monetary Fund.

 

Source : CIA

 

 

SUMMARY

 

Company Name                                     : MULTI APEX PHARMA FOR PHARMACEUTICALS INDUSTRIES

Country of Origin                                    : Egypt

Legal Form                                            : Egyptian Joint Stock Company

Registration Date                                   : 2000

Commercial Registration Number            : 2436, Cairo

Tax Card Number                                   : 205-122-035

Authorised Capital                                  : £E 200,000,000

Issued Capital                                        : £E 120,000,000

Paid up Capital                                      : £E 120,000,000

Total Workforce                                     : 290

Activities                                               : Manufacture of pharmaceutical products.

Financial Condition                                 : Fair

Payments                                             : Nothing detrimental uncovered

Operating Trend                                     : Steady

 

COMPANY NAME

 

MULTI APEX PHARMA FOR PHARMACEUTICALS INDUSTRIES

 

 

company ADDRESS

 

Registered & Physical Address

Street               : 31 Ahmed Omar Bakier Street

Area                 : Heliopolis

Town                 : Cairo

Country             : Egypt

Telephone         : (20-2) 26388608 / 26388404

Facsimile          : (20-2) 26445042

 

Premises

Subject operates from a medium sized suite of offices that are rented and located in the Central Business Area of Cairo.

 

Branch Office (s)

 

     Location                                                                                          Description

 

·       Cairo/Ismailia Road                                                                           Owned laboratory & factory premises

Badr City Industrial Zone, Plot 21D

       Cairo

       Tel: (20-2) 28643001/2/3/4/5/6/7/8

       Fax: (20-2) 28643009

 

·       13 Aflaton Street                                                                               Office premises

Heliopolis

Cairo

Tel: (20-2) 24153009

Fax: (20-2) 24153009

 

 

KEY PRINCIPALS

 

     Name                                                                                              Position

·       Dr Ahmed Essam Ragheb El Ezaby                                                   Chairman

·       Magdy Ali Mohamed Gad Elba                                                           Managing Director

·       Amr Yaccout                                                                                    General Manager

·       Hany Ali                                                                                           Finance Manager

·       Nagi Hassan                                                                                     Sales Manager

 

 

LEGAL FORM & OWNERS

 

Date of Establishment  : 2000

 

Legal Form                  : Egyptian Joint Stock Company

 

Commercial Reg. No.  : 2436, Cairo

 

Tax Card No.               : 205-122-035

 

Authorised Capital       : £E 200,000,000

 

Issued Capital              : £E 120,000,000

 

Paid up Capital            : £E 120,000,000

 

Name of Shareholder (s)                                                       Percentage

 

·       Apex Pharma SAE                                                                65.61%

     13 Aflatoun Street

     Heliopolis

     Cairo 11361

     Tel: (20-2) 26900044 / 24153009

     Fax: (20-2) 4180617

     Email: apex@apexpharma.net

 

·       Multi Apex Pharma                                                                32.31%

 

·       Salem Bawzeer                                                                       2.06%

 

·       Ahmed Essam Ragheb El Ezaby                                              0.02%

 

 

OPERATIONS

 

Activities: Engaged in the manufacture of pharmaceutical products.

 

Import Countries: India, China, France, Spain, Germany, Denmark and the United States of America.

 

Operating Trend: Steady

 

Subject has a workforce of approximately 290 employees.

 

 

FINANCIAL DATA

 

Financial highlights provided by local sources are given below:

 

Currency: Egyptian Pounds (£E)

 

                                                Year Ending 31/12/10:                Year Ending 31/12/11:

 

Total Sales                                £E 95,607,783                           £E 128,000,000

 

Local sources consider subject’s financial condition to be Fair.

 

The above financial figures are based on estimations by our local sources.

 

 

BANKERS

 

·       HSBC Bank Egypt

3 Abul Feda Street

Zamalek

Cairo

Tel: (20-2) 27394748

Fax: (20-2) 27361457

 

·       National Societe Generale Bank

5 Champollion Street

Cairo

Tel: (20-2) 27707777

Fax: (20-2) 27707799

 

 

PAYMENT HISTORY

 

No complaints regarding subject’s payments have been reported.

 

 

GENERAL COMMENTS

 

Local sources report that payment obligations are met in a generally timely manner and the operating history is clear. As such the company is deemed a fair trade risk.

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.55.34

UK Pound

1

Rs.88.50

Euro

1

Rs.70.74

 

INFORMATION DETAILS

 

Report Prepared by :

MNL

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.